AMLX
Amylyx Pharmaceuticals Inc
$29.13
0.16 (0.53%) Today
— up— down
Market Cap
$3.68B+114.6%
Revenue (TTM)
$0
$0Net Income (TTM)
$-159,257,437
$-159,257,437EPS (TTM)
-1.43
-1.43Shares Out
111.19M
111.19MOpen
$29.45
$29.45Previous Close
$29.28
$29.28Day Range
$28.66 – $29.62
$28.66 – $29.6252-Week Range
$10.83 – $41.14
$10.83 – $41.14Beta
-0.10
-0.10Volume
865.15K
865.15KAvg Volume
2.13M
2.13MAnalyst Rating
Buy
BuyExchange
NASDAQ NMS - GLOBAL MARKET
NASDAQ NMS - GLOBAL MARKETAbout AMLX
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.